On February 4, 2026, an Atlanta jury delivered the first-ever bellwether verdict in the Paragard IUD multidistrict litigation — and it went to the defense. The jury in Richard v. CooperSurgical, MDL No. 2974, rejected all claims brought by plaintiff Pauline Rickard, including failure to warn and defective design. For the nearly 4,000 women with active cases in the Northern District of Georgia, that headline may feel devastating. But mass tort litigation rarely moves in a straight line, and one defense verdict in a carefully selected test case does not define what happens to thousands of remaining claims. Here is what the February 2026 result actually means — and why the fall 2026 second bellwether trial may matter far more.
What Happened in the First Paragard IUD Bellwether Trial
Pauline Rickard’s Paragard IUD broke during removal, requiring a hysteroscopy procedure to retrieve device fragments left inside her body. Her attorneys argued that Teva Pharmaceuticals — the original manufacturer — and CooperSurgical, which acquired the device in 2017, failed to adequately warn patients and physicians about the known risk of IUD fracture during removal and that the device itself was defectively designed. After a two-week trial, the jury rejected both theories on every count.
The Paragard IUD is a copper, T-shaped intrauterine device. Unlike hormonal IUDs, it relies entirely on copper’s spermicidal properties. Thousands of women allege that the device’s arms fracture at removal, leaving fragments that migrate or embed in uterine tissue, sometimes requiring hysteroscopies, laparoscopies, or even hysterectomies to address. The FDA’s MAUDE database has received over 7,000 adverse event reports related to Paragard breakage, and the agency initiated a formal safety review of IUD breakage in 2021 before ultimately updating the device’s labeling.
Following the verdict, U.S. District Judge Leigh Martin May signaled she is actively considering adjustments to the MDL bellwether trial plan, and a settlement mediator has already been appointed. Those two developments together tell a more nuanced story than a simple defense win.
Why a Defense Verdict Does Not Doom Remaining Paragard IUD Claims
Bellwether trials serve one primary purpose in mass tort litigation: they give both plaintiffs and defendants a realistic preview of how juries respond to the core legal and scientific arguments in a given MDL. They are test cases by design, not binding precedents. A defense verdict in one bellwether does not legally or practically extinguish the claims of the other plaintiffs in the MDL. Each case is evaluated on its own facts, its own medical evidence, and its own presentation.
Plaintiffs’ attorneys handling Paragard IUD cases have been direct in their post-verdict analysis: case selection and evidence presentation — not the underlying science about device fracture risk — drove the first trial outcome. That is a critical distinction. The biomechanical and metallurgical evidence that Paragard arms break during removal at rates far exceeding other IUDs did not disappear because one jury was unpersuaded. A peer-reviewed study published in the journal Contraception found that copper IUD breakage was recorded in 9.6% of adverse events, compared to just 1.7% for hormonal IUDs — a statistically significant disparity that will remain available to plaintiffs in every future trial. You can use a medical malpractice calculator to explore how documented device injuries and resulting medical procedures factor into compensation estimates for defective medical device claims.
Post-verdict, plaintiff firms across the country are already tightening their case intake processes to prioritize plaintiffs with imaging-confirmed fractures and well-documented medical treatment histories. That strategic sharpening is a direct response to what the first trial exposed about proof gaps — not a retreat from the litigation itself.
Key MDL Data: Paragard IUD Cases at a Glance (2026)
| Metric | Current Data (2026) | Source |
|---|---|---|
| Active MDL Cases (as of May 2026) | 3,984 | MDL Case Report |
| New Filings Per Month | 22+ | MDL Docket Monitoring |
| Cases Added March–April 2026 | 56 | MDL Docket Monitoring |
| Cases Added April–May 2026 | 2 | MDL Docket Monitoring |
| FDA Adverse Event Reports (Paragard Breakage) | 7,000+ | FDA MAUDE Database |
| Copper IUD Breakage Rate in Adverse Events | 9.6% | Contraception Journal Study |
| Hormonal IUD Breakage Rate in Adverse Events | 1.7% | Contraception Journal Study |
| First Bellwether Verdict Date | February 4, 2026 | MDL 2974 Court Record |
| Second Bellwether Trial (Projected) | Fall 2026 | MDL 2974 Scheduling Order |
| Third Bellwether Trial | Late 2026 | MDL 2974 Calendar |
The Fall 2026 Second Bellwether and What It Means for Settlement
The second Paragard IUD bellwether trial was originally scheduled for spring 2026. It has since been pushed to fall 2026, with the court giving both sides additional time to work through remaining expert discovery issues and to absorb lessons from the first trial. A third bellwether remains on the calendar for later in 2026 as well. This compressed but still active schedule matters enormously for settlement dynamics.
In virtually every large MDL, the realistic path to a global resolution runs through the bellwether process. Defendants need to see whether a plaintiff verdict is achievable before they will seriously engage on compensation numbers. Plaintiffs need the same data to calibrate settlement demands. The February 2026 defense verdict gave Teva and CooperSurgical some leverage — but a single data point is not enough to anchor a global settlement affecting nearly 4,000 active claimants. The fall 2026 second bellwether, combined with the judge’s appointment of a settlement mediator, suggests that both sides are already positioning for a negotiated resolution rather than trying thousands of individual cases. Federal court MDL procedures are specifically designed to funnel mass cases toward resolution once the trial record matures.
For injured women monitoring this litigation, the fall 2026 trial is the next genuinely important milestone. If plaintiffs win that trial — or even achieve a close, contested loss — the pressure on defendants to settle meaningfully increases substantially. Women who have suffered documented Paragard IUD fractures, retained device fragments, or required surgical intervention have strong incentives to have their claims properly documented and filed before any global settlement discussions accelerate.
What Women With Paragard IUD Injuries Should Know Right Now
The first bellwether loss does not change the underlying legal landscape for women injured by a fractured Paragard IUD. What it does change is the evidentiary bar that plaintiff attorneys expect juries to require. Going forward, the strongest Paragard IUD claims will share several common characteristics: imaging evidence confirming device fracture or retained fragments, documented medical interventions such as hysteroscopy or hysterectomy directly related to the fracture, treating physician records connecting the injury to the device, and a clear timeline linking removal attempts to the breakage event.
Women whose Paragard IUD broke during removal, who experienced unexplained pelvic pain after removal attempts, or who were told by a provider that device fragments remained should have their medical records reviewed as soon as possible. Filing deadlines under applicable statutes of limitations vary by state, and with 22 or more new cases entering the MDL every month through 2026, the litigation remains fully active. You can also explore a personal injury settlement calculator to better understand how medical expenses, surgical costs, lost wages, and pain and suffering are typically quantified in mass tort claims before consulting an attorney.
The MDL’s case count growth — 56 new filings in just the March–April 2026 period alone — reflects ongoing awareness among injured patients and their providers. The litigation is not winding down following the defense verdict. It is, in many respects, entering its most consequential phase, with a settlement mediator in place, a second bellwether imminent, and a judge already reconsidering the trial plan structure.
Frequently Asked Questions About the Paragard IUD MDL Verdict
Does the February 2026 defense verdict mean my Paragard IUD case has no value?
No. Bellwether verdicts in MDL litigation are test cases designed to inform both sides about jury responses to the evidence — they are not binding on any other plaintiff’s claim. Each case in the MDL is evaluated individually. The defense verdict in Richard v. CooperSurgical tells both sides how one jury responded to one plaintiff’s specific evidence, but it does not legally determine the outcome of the nearly 4,000 remaining cases. The scientific data on Paragard breakage rates, the FDA’s adverse event records, and the peer-reviewed research on copper IUD fractures all remain available to future plaintiffs.
What is a bellwether trial and why does it matter for mass torts?
A bellwether trial is a representative test case selected from a larger MDL to be tried before a jury so both sides can assess litigation risk. Courts use bellwether trials to expose strengths and weaknesses in the evidence, reveal how juries respond to expert testimony, and generate settlement pressure. In the Paragard IUD MDL, the first bellwether produced a defense verdict, but the second and third bellwethers scheduled for fall and late 2026 will provide additional data points that more fully shape global settlement negotiations. Cornell Law School’s Legal Information Institute provides a useful overview of how MDL procedures work in federal court.
When is the next Paragard IUD bellwether trial scheduled?
The second Paragard IUD bellwether trial has been pushed from spring 2026 to fall 2026. The delay was granted to allow both sides to conduct remaining expert discovery and to process lessons from the first trial. A third bellwether trial also remains on the calendar for later in 2026. Judge Leigh Martin May is also considering adjustments to the overall bellwether trial plan following the February 4, 2026 defense verdict. These upcoming trials are the next major milestones for the approximately 3,984 active claimants in the MDL as of May 2026.
How does a global settlement work in a mass tort MDL like the Paragard IUD case?
A global settlement in an MDL typically occurs after enough bellwether trials have been completed to give defendants and plaintiffs a realistic picture of their respective litigation risks. The presiding judge facilitates the process — in the Paragard IUD MDL, Judge May has already appointed a settlement mediator. Both sides then negotiate a total settlement fund that is allocated among eligible claimants based on injury severity, documented medical treatment, and other factors established by a settlement matrix. Individual plaintiffs must affirmatively accept any settlement offer, but the mediator and attorneys work to achieve a resolution that covers the majority of pending claims efficiently.
What types of Paragard IUD injuries are most likely to qualify for compensation?
The strongest Paragard IUD claims involve documented evidence of device fracture during removal, imaging confirmation of retained device fragments, and medical records showing surgical intervention — such as hysteroscopy, laparoscopy, or hysterectomy — directly caused by the retained fragments. Following the February 2026 defense verdict, plaintiff attorneys are prioritizing cases with imaging-confirmed fractures and clear medical documentation chains. Women who experienced device breakage, unexplained pelvic pain after removal, or were informed by providers that device pieces remained should gather all relevant medical imaging, surgical reports, and provider notes as a first step toward evaluating their claim.
This article is provided for general informational purposes only and does not constitute legal advice; readers with specific legal questions about the Paragard IUD MDL or related personal injury claims should consult a licensed attorney in their jurisdiction.
Related reading: medical malpractice calculator
Related reading: medical malpractice calculator
Victoria Chambers is a mass tort and class action research analyst with extensive knowledge of multi-district litigation (MDL), defective product cases, dangerous drug lawsuits, and toxic exposure claims across the United States. Victoria is not an attorney and the information provided is for educational purposes only.